Bursill on treat-to-target gout therapy and the under-treatment gap
What if your gout could actually be cured, not just managed flare by flare?
Episode aired Jun 19, 2023·Page synthesised Jun 8, 2026·Last reviewed Jun 9, 2026
What this episode covers
- Gout is a chronic metabolic disease, not just a series of painful flares.
- Long-term treat-to-target therapy with allopurinol can dissolve existing crystal deposits and may allow prolonged remission or clinical cure in some patients.
- The biggest barrier is not difficulty of treatment but how often gout is undertreated, often because patients and clinicians focus on flares rather than long-term urate control.
- Diet alone is rarely sufficient; medication usually is.
Why it matters
If gout can often be cured rather than only managed, then treating it as a chronic medical disease (rather than a dietary embarrassment) matters across joint health, kidney function, cardiovascular risk, and quality of life for years to come. Persistent gout is associated with increased risk of chronic kidney disease and cardiovascular disease, although the extent to which gout itself contributes beyond shared risk factors remains an active area of research.
What stands out
- Gout can often be clinically cured through sustained long-term urate-lowering therapy, not just managed flare by flare (Gout, Hyperuricemia and Crystal-Associated Disease Network consensus + Bursill clinical experience)
- Most gout patients are significantly undertreated, often because both they and their clinicians focus on flares rather than long-term urate control (international rheumatology under-treatment analyses)
- Diet matters, but it usually cannot overcome impaired urate handling; most uric acid problems stem from kidney-clearance factors that are largely genetic (genetic and pharmacology research)
Best-supported action
The single highest-leverage move from this episode, anchored in the strongest evidence the speaker presents.
If you have had two or more gout flares, ask your doctor whether long-term urate-lowering therapy such as allopurinol would be appropriate and what serum uric acid target you should aim for.
Where to start
Small low-friction starters covering the main moves from this episode.
- Reduce sugar-sweetened drinks and beer first if these are part of your routine — both are well-documented gout triggers and the lifestyle move sits below any medication conversation
- Track flare frequency and severity for two months so the conversation with your doctor about long-term therapy is grounded in actual data, not impression
- If you have had two or more gout flares, ask your doctor whether long-term urate-lowering therapy (allopurinol) would be appropriate and what serum urate target to aim for — under 6 mg/dL is the threshold below which crystal deposits dissolve over time
Other supported actions
Further actions discussed in this episode, ordered from strongest to weakest evidence. This is one expert's view, the full topic compares and ranks across experts.
- Consider asking your doctor whether early urate-lowering therapy would be appropriate in your situation, particularly if you have recurrent flares, high uric acid levels, kidney disease, tophi, or a strong family history; serum uric acid checks every 4-6 weeks during dose titration are standard.Strong evidence
- Consider continuing urate-lowering therapy indefinitely once your serum uric acid is at target, even when no flares occur — stopping often leads to rising uric acid levels within weeks and eventual return of flares.Strong evidence
- Consider asking your clinician what your current serum uric acid level is and whether you are at the 6 mg/dL target, rather than only discussing flare frequency.Moderate evidence
Full context, impact ratings, and timing — available in related topics
Questions to take to your doctor
- Given my gout history, am I currently on urate-lowering therapy, and if so, what is my current serum uric acid target?
- Given that I've had multiple flares, should we titrate my allopurinol dose higher to reach the 6 mg/dL target?
- Given the under-treatment gap in gout, what specifically would change about my treatment if we focused on long-term urate control rather than flare management?
Full doctor prep with ranked questions available in the full topic page
Context
Consultant rheumatologist and crystal-disease nomenclature researcher. Tends to view gout as a chronic metabolic disease that is highly treatable when approached systematically with treat-to-target urate-lowering therapy, and argues forcefully that the biggest barrier is the persistent under-treatment gap rather than the difficulty of treatment itself. Strongest on gout management discipline and crystal-disease nomenclature; less involved in broader rheumatology or non-crystal arthritis research.
This does not prove that all gout patients respond identically to urate-lowering therapy; some require different drugs or higher doses.
This does not prove that diet is irrelevant; modest dietary changes still help on the margins.
This does not prove that complete clinical cure is achievable for every patient; chronic management remains the realistic expectation for many.
This does not mean you should change or stop any current medical treatment on your own.
Where people go wrong
- Treating gout as a series of flares to react to rather than a chronic metabolic disease to manage long-term.May lead to permanent joint damage, kidney effects, and cardiovascular risk over years, even when individual flares get treated promptly. The flare is a symptom; the urate burden is the disease.
- Stopping urate-lowering medication when flares stop or feeling better.Serum uric acid typically rises again within weeks of stopping medication, and flares often return. Sustained therapy is required to dissolve existing crystal deposits and prevent new ones.
What to expect over time
- Weeks 1 to 6Start urate-lowering therapy. Expect dose titration with serum uric acid checks every 4-6 weeks. Some patients experience increased flares during initiation, which is paradoxical but expected as crystals begin to dissolve; flare-prevention medication is often co-prescribed.
- Months 2 to 12Continue titration until serum uric acid is consistently below 6 mg/dL. Flare frequency typically decreases substantially. Many patients see no flares after the first 6 months at target.
- Year 2 and beyondSustained therapy at target slowly dissolves existing crystal deposits and can lead to long periods without flares. Whether medication can safely be stopped after years of sustained control varies between patients and should be discussed with a clinician. Most continue therapy indefinitely as preventive care.